GPC3 and hepatocellular carcinoma: Compared to CAR-Glypican-3 T-Cell therapy for advanced HCC, the incidence and severity of AEs after HBV-TCR-T-cell immunotherapy in our study was lower and less frequent, and had no neurotoxicity, cytokine release syndrome, or WBC, lymphocyte and platelet count reduction.